Angiotensin Converting Enzymes (ACE) Inhibitors Market Expected to Expand at a Steady 2021-2028 | Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG

Angiotensin converting enzymes inhibitors are used for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraine. Frequently prescribed angiotensin converting enzyme (ACE) inhibitors include benazepril, perindopril, trandolapril, captopril, enalaopril, lisinopril, and ramipril. Moreover, ACE inhibitors are the first choice drugs by healthcare providers for the treatment of hypertension.

The global angiotensin converting enzymes (ACE) inhibitors market was valued at US$ 11,693.6 million in 2017 and is expected to exhibit a CAGR of 0.8% over the forecast period (2018-2026).

To Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2746

Increasing prevalence of hypertension is expected to drive growth of the angiotensin converting enzymes (ACE) inhibitors market

Increasing prevalence of hypertension is one of the major drivers for the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, according to the World Health Organization’s (WHO) report, 2018, around 207 million people including 112 million men and 95 million women suffer from hypertension, annually in India.

Moreover, increasing number of research and development activities for improvement of cardiovascular functions during pregnancy is expected to propel the angiotensin converting enzyme (ACE) inhibitors market growth over the forecast period. For instance, in September 2018, Manchester University NHS Foundation Trust initiated clinical Phase II study of Enalapril Maleate for the pre-eclampsia condition. This study is for evaluating drug safety and efficacy on the patients. Pre-eclampsia condition is a pregnancy complication characterized by high blood pressure. It has various signs and symptoms including proteinuria, upper abdominal pain, and shortness of breath.
Angiotensin Converting Enzymes (ACE) Inhibitors Market - Regional Analysis

Regional segmentation of the global angiotensin converting enzymes (ACE) inhibitors market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America angiotensin converting enzymes (ACE) inhibitors market is expected to account for the largest market share over the forecast period, owing to increasing product approvals by the U.S. Food and Drug Administration (FDA). For instance, in August 2016, Silvergate Pharmaceutical Inc. received the U.S. FDA approval for its Qbrelis, containing Lisinopril, an oral solution 1 mg/ml. This drug is indicated for the treatment of hypertension in adult and children.

For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/2746

Moreover, Europe is expected to gain significant share in the global angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing product launches in the region. For instance, in September 2012, France-based Ceva Sante Animale S. A. launched its new combination drug, Benazepril and Spironolactone Tablet, for the treatment of heart failure in humans as well as in dogs.

Asia Pacific is also expected to witness significant growth in the angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing awareness activities regarding hypertension and its prevention in this region. For instance, in May 2018, Indian Council of Medical Research (ICMR) organized an awareness campaign on hypertension in collaboration with Public Health Foundation of India. According to ICMR, around 10.8% deaths annually caused by hypertension in India. Therefore, such programs are expected to increase awareness for the treatment and management of hypertension, which is further expected to fuel the ACE inhibitors market growth in the region.

Angiotensin Converting Enzymes (ACE) Inhibitors Market - Competitive Landscape

Key players operating in the angiotensin converting enzymes (ACE) inhibitors market include Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and Bayer AG.

To Direct Purchase this Premium Research Report – https://www.coherentmarketinsights.com/insight/buy-now/2746

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.